Inducible Mouse Models for Cancer Drug Target Validation. - Wikidata - wikimedia - TriplyDB

Inducible Mouse Models for Cancer Drug Target Validation.

Inducible Mouse Models for Cancer Drug Target Validation.

http://www.wikidata.org/entity/Q37552307

about

The Oncopig Cancer Model as a Complementary Tool for Phenotypic Drug Discovery.

P2860

Q47128290-84465435-6ACD-42C5-AF3D-A92BCECEBAF4

P2860

Inducible Mouse Models for Cancer Drug Target Validation.

http://www.wikidata.org/entity/Q37552307

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 30 December 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Inducible Mouse Models for Cancer Drug Target Validation.

@en

Inducible Mouse Models for Cancer Drug Target Validation.

@nl

type

label

Inducible Mouse Models for Cancer Drug Target Validation.

@en

Inducible Mouse Models for Cancer Drug Target Validation.

@nl

prefLabel

Inducible Mouse Models for Cancer Drug Target Validation.

@en

Inducible Mouse Models for Cancer Drug Target Validation.

@nl

P1433

Q37552307-5FB134E1-75CA-47E4-A9F0-1562A794B4F4

P1476

Q37552307-C9ACCF29-3510-432D-8A1B-CBFBBD04C407

P2093

Q37552307-28DB6DDA-2679-40E0-AA5C-89A4894ABE09

P2860

Q37552307-10B79CC1-F310-4339-AACF-9194D5AF727B

Q37552307-12E0407D-20D6-4D8E-9810-C8B1FC446BE5

Q37552307-18A33F15-D995-47DC-B004-61C35160B2E6

Q37552307-1C5A6201-5CFD-4220-B99C-087DD23764EE

Q37552307-1FB0433B-5DAD-43EA-B39F-2B057D90089F

Q37552307-2DB2DFB8-1AED-4AFC-9F7F-D5D72DEDAD56

Q37552307-30D624F8-622F-428A-94FD-B26F468631B6

Q37552307-3C923B94-E2A1-439A-9F3B-2BE1B5E37C4C

Q37552307-4043E52A-B5E6-48DF-94FC-2C79A77A7A57

Q37552307-40A11BDC-3A97-4DF3-AF47-B4E0B1A3D117

P304

Q37552307-7F825BE5-C920-49B4-87F8-1011CF870B93

P31

Q37552307-4CD7BEC5-A5D9-457D-85CB-AD9C2C777F3B

P356

Q37552307-16B95B8F-A7B9-440C-8D2B-B72F57285EBD

P433

Q37552307-7BD1C68C-3C65-465C-A4B4-CE07005ECF66

P478

Q37552307-EBBA697D-15F4-422B-907F-EBA530A93842

P577

Q37552307-B6C2C8CB-39B6-4BA3-9CED-24B94FE1B5AF

P698

Q37552307-9A946D43-90F0-47E7-BE24-58BF4D5659CC

P932

Q37552307-9B5955B4-8B16-47F8-8FA7-1E9527BFAAE2

P356

JCP.2016.21.4.243

P1433

Journal of cancer prevention

P1476

Inducible Mouse Models for Cancer Drug Target Validation.

@en

P2093

Joseph H Jeong

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Comprehensive molecular portraits of human breast tumours

Mouse xenograft models vs GEM models for human cancer therapeutics

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation

Concise review: humanized models of tumor immunology in the 21st century: convergence of cancer research and tissue engineering

Tetracyclines Disturb Mitochondrial Function across Eukaryotic Models: A Call for Caution in Biomedical Research

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

P304

243-248

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.15430/JCP.2016.21.4.243

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28053958

http://www.w3.org/2001/XMLSchema#string

P932

5207608

http://www.w3.org/2001/XMLSchema#string